AMENDMENT

Listing of Claims:

The following listing of claims replaces all previous listings or versions thereof:

- 1-37. (Canceled)
- 38. (Previously Presented) A method of screening for modulators of a lipopolysaccharide mediated response comprising the steps of:
 - a) obtaining a cell expressing a TLR-4 polypeptide;
 - b) measuring a lipopolysaccharide mediated response mediated by the TLR-4 polypeptide;
 - c) contacting the TLR-4 polypeptide with a putative modulator;
 - d) assaying for a change in the lipopolysaccharide mediated response; and
 - e) comparing the lipopolysaccharide mediated responses mediated by the TLR-4 polypeptide obtained in steps b) and d) above

wherein a difference in the lipopolysaccharide mediated responses indicates that the putative modulator is a modulator of a lipopolysaccharide mediated response.

- 39. (Original) The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 or SEQ ID NO:99.
- 40. (Previously Presented) The method of claim 39, wherein the lipopolysaccharide mediated response mediated by the TLR-4 polypeptide is determined by determining the ability of the TLR-4 polypeptide to stimulate transcription of a reporter gene, the reporter gene operatively positioned under control of a nucleic acid segment comprising a promoter from a TLR-4 gene.

41-51. (Canceled)

- 52. (Previously Presented) The method of claim 38, wherein said putative modulator is effective in altering the mediation of the lipopolysaccharide mediated response by TLR-4.
- 53. (Previously Presented) The method of claim 52, wherein said putative modulator is an agonist.
- 54. (Previously Presented) The method of claim 52, wherein said putative modulator is an antagonist.
- 55. (Previously Presented) The method of claim 52, wherein said putative modulator affects the transcription of TLR-4.
- 56. (Previously Presented) The method of claim 52, wherein said putative modulator affects the translation of TLR-4.
- 57. (Previously Presented) The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:2.
- 58. (Previously Presented) The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:4.
- 59. (Previously Presented) The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:6.
- 60. (Previously Presented) The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:98.
- 61. (Previously Presented) The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence of SEQ ID NO:99.

- 62. (Canceled)
- 63. (Previously Presented) The method of claim 38, wherein said putative modulator inhibits TLR-4 directed signaling of TNF secretion.
- 64. (Previously Presented) The method of claim 38, wherein said putative modulator stimulates TLR-4 directed signaling of TNF secretion.
- 65. (Previously Presented) The method of claim 38, wherein said putative modulator to be screened is obtained from a library of synthetic chemicals.
- 66. (Previously Presented) The method of claim 38, wherein said putative modulator to be screened is obtained from a natural source.
- 67. (Currently Amended) The method of claim 6566, wherein said natural source is selected from the group consisting of animals, bacteria, fungi, plant sources and living marine samples.
- 68. (Previously Presented) The method of claim 38, wherein said putative modulator to be screened is a protein or peptide.
- 69. (Canceled)
- 70. (Previously Presented) The method of claim 38, wherein said putative modulator to be screened is a nucleic acid molecule.
- 71. (Previously Presented) The method of claim 38, wherein said putative modulator to be screened is a stimulator of an immune response.
- 72. (Previously Presented) The method of claim 71, wherein said stimulator of an immune response is a cytokine.

- 73. (Previously Presented) The method of claim 71, wherein said stimulator of an immune response is an interferon.
- 74. (Previously Presented) The method of claim 38, wherein said TLR-4 polypeptide is encoded by a nucleic acid sequence selected from the group comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:46, SEQ ID NO:47 and SEQ ID NO:48.
- 75. (Previously Presented) The method of claim 38, wherein said putative modulator to be screened is an IL-1 receptor antagonist.

76-99. (Canceled)

- 100. (Previously Presented) The method of claim 38, wherein the TLR-4 polypeptide has the amino acid sequence selected from the group comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:98 and SEQ ID NO:99.
- 101. (Previously Presented) The method of claim 38, wherein said putative modulator to be screened is a small molecule.
- 102. (Previously Presented) The method of claim 101, wherein said small molecule inhibits TLR-4 mediation of the lipopolysaccharide mediated response.
- 103. (Previously Presented) The method of claim 101, wherein said small molecule inhibits the lipopolysaccharide mediated response.